Carl Conway

Genomic medicine for kidney disease

Latest Reviews

  • Review |

    Some animals have developed mechanisms to protect them from environmental stresses, whereas others remain susceptible. Here, Stenvinkel et al. discuss how a better understanding of susceptibility and protective mechanisms could provide insights to novel strategies for the prevention and treatment of several human diseases, such as chronic kidney disease and ageing-associated complications.

    • Peter Stenvinkel
    • , Johanna Painer
    • , Makoto Kuro-o
    • , Miguel Lanaspa
    • , Walter Arnold
    • , Thomas Ruf
    • , Paul G. Shiels
    •  & Richard J. Johnson
  • Review |

    Genomic medicine approaches are increasingly used for diagnosis of kidney disease. Here, the authors discuss sequencing modalities, the interpretation and clinical application of genetic data, and the challenges that must be overcome to realize the potential of genomic medicine in nephrology.

    • Emily E. Groopman
    • , Hila Milo Rasouly
    •  & Ali G. Gharavi
  • Review |

    Sepsis induces an initial activation of the immune system, which is often followed by a compensatory anti-inflammatory response that can lead to immunosuppression. In this Review, the authors discuss advances in the understanding of sepsis-induced immunosuppression and how this understanding might lead to new, more effective treatments for sepsis.

    • Fabienne Venet
    •  & Guillaume Monneret
  • Review |

    Adipose is an important endocrine and immunologic organ, releasing various adipokines and cytokines that regulate the adipocyte microenvironment and systemic metabolism. Here, the authors discuss the immunologic and endocrine functions of adipose tissue that contribute to kidney disease and the converse effects of kidney dysfunction on adipose tissue.

    • Qingzhang Zhu
    •  & Philipp E. Scherer
  • Review |

    Complement activation has important physiological and pathological implications for kidney-related and other diseases. Here, the authors discuss the state of the art of complement therapeutics, including the targets, candidate drugs, insights from clinical trials and evolving challenges for the field.

    • Daniel Ricklin
    • , Dimitrios C. Mastellos
    • , Edimara S. Reis
    •  & John D. Lambris
  • Review |

    Dyslipidaemia is a common consequence of nephrotic syndrome, and results in various cardiovascular and metabolic complications. In this Review, the authors discuss the mechanisms that underlie the development of dyslipidaemia, and the treatment options that are available to ameliorate its effects.

    • Shipra Agrawal
    • , Joshua J. Zaritsky
    • , Alessia Fornoni
    •  & William E. Smoyer

News & Comment

Natureevents Directory